Table of contents
March 2002 Vol 1 No 3
In this issue
p165 | doi:10.1038/nrn762
Editorial: Fuelling the pipeline
p167 | doi:10.1038/nrd767
Research Highlights
Obesity: PPAR
2 piles on the pounds
p169 | doi:10.1038/nrd755
Metabolic disorders: Insulin mimetics
p170 | doi:10.1038/nrd754
Structure-based drug design: Turning Ying into Yang
p170 | doi:10.1038/nrd758
Analgesia: Dial 'P' for pain
p171 | doi:10.1038/nrd763
Microbial disease: Part three of the anthrax trilogy
p172 | doi:10.1038/nrd757
Analgesia: Ecstatic about RAVE
p172 | doi:10.1038/nrd759
Anti-inflammatories: No bones about it
p173 | doi:10.1038/nrd764
In brief
Analgesia | Kidney disease | Neurodegenerative disease
p173 | doi:10.1038/nrd765
In vivo screening: Vascular maps
p174 | doi:10.1038/nrd761
Reviews
Building drug delivery into tissue engineering design
W. Mark Saltzman & William L. Olbricht
p177 | doi:10.1038/nrd744
Regulators of G-Protein signalling as new central nervous system drug targets
Richard R. Neubig & David P. Siderovski
p187 | doi:10.1038/nrd747
Allosteric binding sites on cell-surface receptors: novel targets for drug discovery
Arthur Christopoulos
p198 | doi:10.1038/nrd746
Nmr in drug discovery
Maurizio Pellecchia, Daniel S. Sem & Kurt Wüthrich
p211 | doi:10.1038/nrd748
Chemical database techniques in drug discovery
Mitchell A. Miller
p220 | doi:10.1038/nrd745
Perspectives
Business outlook: Development of therapeutics: opportunities within complementary and alternative medicine
Linda W. Engel & Stephen E. Straus
p229 | doi:10.1038/nrd750
Opinion
The role of pharmacology in drug discovery
Bertil B. Fredholm, William W. Fleming, Paul M. Vanhoutte & Théophile Godfraind
p237 | doi:10.1038/nrd749
Innovation
Indirect monitoring of lung inflammation
Paolo Montuschi
p238 | doi:10.1038/nrd751
Careers and Recruitment
Can master craftsmen be mass-produced?
Richard Archer, CEO
p245 | doi:10.1038/nrd760
